Rayner Hugh C, Pisoni Ronald L, Gillespie Brenda W, Goodkin David A, Akiba Takashi, Akizawa Tadao, Saito Akira, Young Eric W, Port Friedrich K
Department of Renal Medicine, Birmingham Heartlands Hospital, Birmingham, United Kingdom.
Kidney Int. 2003 Jan;63(1):323-30. doi: 10.1046/j.1523-1755.2003.00724.x.
An arteriovenous (A-V) fistula is the optimal vascular access for hemodialysis. The National Kidney Foundation Dialysis Outcomes Quality Initiative (DOQI) recommends that fistulae should mature for at least one month before cannulation, but this recommendation is not evidence-based. If fistulae are created prior to ESRD and cannulation is possible earlier without compromising fistula survival, the need for temporary catheters would be reduced.
Prospective observational data were analyzed for a random sample (N = 3674) of incident patients at the time of initiating hemodialysis, hemofiltration or hemodiafiltration in 309 facilities in France, Germany, Italy, Japan, Spain, the United Kingdom, and the United States, taking part in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
Although the proportion of patients who had pre-dialysis care by a nephrologist differed little between countries, there were large variations in the proportion of patients who commenced hemodialysis via an A-V fistula, A-V graft or central venous catheter. The usual time interval between referral and creation of A-V fistulae also differed greatly between countries. For new hemodialysis (HD) patients initiating HD with an A-V fistula (N = 894) the following results were observed: (1). median time to first cannulation varied greatly between countries: Japan and Italy (25 and 27 days), Germany (42 days), Spain and France (80 and 86 days), UK and US (96 and 98 days). (2). No association was found between cannulation <or=28 days versus>28 days for patient characteristics of age, gender, and fifteen different classes of patient co-morbid factors. (3). Risk of A-V fistula failure was increased for incident patients who had a prior temporary access [relative risk (RR) = 1.81, P = 0.01] or who were female (RR = 1.52, P = 0.02). (4). Cannulation <or=14 days after creation was associated with a 2.1-fold increased risk of subsequent fistula failure (P = 0.006) compared to fistulae cannulated>14 days. (5) No significant difference in A-V fistula failure was seen for fistulae cannulated in 15 to 28 days compared with 43 to 84 days.
Significant differences in clinical practice currently exist between countries regarding the creation of A-V fistulae prior to starting hemodialysis and the timing of initial cannulation. Cannulation within 14 days of creation is associated with reduced long-term fistula survival. Fistulae ideally should be left to mature for at least 14 days before first cannulation.
动静脉内瘘是血液透析的最佳血管通路。美国国家肾脏基金会透析预后质量倡议(DOQI)建议内瘘在穿刺前应至少成熟1个月,但这一建议并非基于证据。如果在内分泌性肾衰(ESRD)之前建立内瘘,并且能在不影响内瘘存活的情况下更早进行穿刺,那么对临时导管的需求将会减少。
对法国、德国、意大利、日本、西班牙、英国和美国309家医疗机构中开始进行血液透析、血液滤过或血液透析滤过的初诊患者随机样本(N = 3674)的前瞻性观察数据进行分析,这些数据来自参与透析预后与实践模式研究(DOPPS)的机构。
尽管各国由肾病科医生进行透析前护理的患者比例差异不大,但通过动静脉内瘘、动静脉移植物或中心静脉导管开始血液透析的患者比例存在很大差异。各国在内瘘转诊与建立之间的通常时间间隔也有很大不同。对于以动静脉内瘘开始血液透析(HD)的新患者(N = 894),观察到以下结果:(1)首次穿刺的中位时间在各国之间差异很大:日本和意大利(分别为25天和27天)、德国(42天)、西班牙和法国(分别为80天和86天)、英国和美国(分别为96天和98天)。(2)对于年龄、性别以及十五种不同类别的患者合并症因素等患者特征,在穿刺≤28天与>28天之间未发现关联。(3)有过临时通路的初诊患者(相对风险(RR)= 1.81,P = 0.01)或女性患者(RR = 1.52,P = 0.02)动静脉内瘘失败的风险增加。(4)与穿刺时间>14天的内瘘相比,在建立后≤14天进行穿刺与随后内瘘失败风险增加2.1倍相关(P = 0.006)。(5)在15至28天穿刺的内瘘与在43至84天穿刺的内瘘相比,动静脉内瘘失败无显著差异。
目前各国在开始血液透析前动静脉内瘘的建立以及首次穿刺时间方面的临床实践存在显著差异。在建立后14天内进行穿刺与内瘘长期存活降低相关。理想情况下,内瘘在首次穿刺前应至少成熟14天。